1-20 of 35
Ji Youn Han
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker Lung Adenocarcinoma Patients without EGFR or ALK Alterations

Seung-Jin Park, Shinyeong Ju, Sung-Ho Goh, Byoung-Ha Yoon, Jong-Lyul Park, Jeong-Hwan Kim, Seonjeong Lee, Sang-Jin Lee, Yumi Kwon, Wonyeop Lee, Kyung Chan Park, Geon Kook Lee, Seog Yun Park, Sunshin Kim, Seon-Young Kim, Ji-Youn Han, Cheolju Lee
Journal: Cancer Research
Cancer Res (2024) 84 (9): 1491–1503.
https://doi.org/10.1158/0008-5472.CAN-23-1551
Published: 02 May 2024
View articletitled, Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker Lung Adenocarcinoma Patients without EGFR or ALK Alterations
Open the PDF for Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker Lung Adenocarcinoma Patients without EGFR or ALK Alterations in another window
Includes: Supplementary data
Journal Articles

Abstract CT154: Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI, in patients with 3rd generation EGFR-TKI resistance in EGFR mutated advanced/metastatic non-small cell lung cancer (NSCLC)

Sun Min Lim, Byoung Chul Cho, Ji Youn Han, Sang We Kim, Ki Hyeong Lee, Misako Nagasaka, Anna Jo, Ethan Seah, Choonok Kim, Thanyanan Reungwetwattana
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT154.
https://doi.org/10.1158/1538-7445.AM2024-CT154
Published: 05 April 2024
View articletitled, Abstract CT154: Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI, in patients with 3rd generation EGFR-TKI resistance in EGFR mutated advanced/metastatic non-small cell lung cancer (NSCLC)
Journal Articles

Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors

Yonina R. Murciano-Goroff, Rebecca S. Heist, Yasutoshi Kuboki, Takafumi Koyama, Natraj Reddy Ammakkanavar, Antoine Hollebecque, Amita Patnaik, Toshio Shimizu, Alexander I. Spira, Misako Nagasaka, Ji-Youn Han, Wade Thomas Iams, Dustin Deming, Justin Call, Philippe Cassier, Sae-Won Han, Quincy Siu-chung Chu, Rasha Cosman, Gregory Durm, Timothy Burns, Melinda D. Willard, Shiyao Liu, Sophie Callies, Arjun V. Balar, Joshua K. Sabari
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT028.
https://doi.org/10.1158/1538-7445.AM2023-CT028
Published: 14 April 2023
View articletitled, Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors
Journal Articles

Abstract 2805: Pharmacogenomic platform using patient-derived cells to delineate tumor heterogeneity and therapeutic response of refractory lung cancer

Charny Park, Sehwa Hong, Mihwa Hwang, Youngjoo Lee, Bo Ram Song, Eun Hye Kang, Hanna Sim, Beung-Chul Ahn, Kum Hui Hwang, Namhee Yu, Sunshin Kim, Ji-Youn Han
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 2805.
https://doi.org/10.1158/1538-7445.AM2023-2805
Published: 04 April 2023
View articletitled, Abstract 2805: Pharmacogenomic platform using patient-derived cells to delineate tumor heterogeneity and therapeutic response of refractory lung cancer
Journal Articles

Abstract 2806: Patient-derived cell-based pharmacogenomic platform to uncover resistance mechanisms and novel therapeutics for advanced lung cancer

Charny Park, Namhee Yu, Mihwa Hwang, Youngjoo Lee, Bo Ram Song, Eun Hye Kang, Hanna Sim, Beung-Chul Ahn, Kum Hui Hwang, Sehwa Hong, Sunshin Kim, Ji-Youn Han
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 2806.
https://doi.org/10.1158/1538-7445.AM2023-2806
Published: 04 April 2023
View articletitled, Abstract 2806: Patient-derived cell-based pharmacogenomic platform to uncover resistance mechanisms and novel therapeutics for advanced lung cancer
Journal Articles

Abstract 4929: ICX-101, a novel MYC inhibitor, shows antitumor activity in patient-derived cells of advanced lung cancer with high MYC expression

Wonyoung Choi, Kyung-Chae Jeong, Seog-Yun Park, Sunshin Kim, Eun Hye Kang, Mihwa Hwang, Ji-Youn Han
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 4929.
https://doi.org/10.1158/1538-7445.AM2023-4929
Published: 04 April 2023
View articletitled, Abstract 4929: ICX-101, a novel MYC inhibitor, shows antitumor activity in patient-derived cells of advanced lung cancer with high MYC expression
Journal Articles

Abstract 5235: The role of transient single MET inhibition in MET-amplified and EGFR-mutant nonsmall cell lung cancer resistant to EGFR inhibitors

Youngjoo Lee, Yu-Ra Choi, Eun Hye Kang, Sunshin Kim, SeogYun Park, Ji-Youn Han
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 5235.
https://doi.org/10.1158/1538-7445.AM2022-5235
Published: 15 June 2022
View articletitled, Abstract 5235: The role of transient single MET inhibition in MET-amplified and EGFR-mutant nonsmall cell lung cancer resistant to EGFR inhibitors
Journal Articles

Abstract 5209: Hyperprogression in various solid cancers treated with immune checkpoint inhibitors in the real world

Jwa Hoon Kim, Soohyeon Lee, Min Hee Hong, Jee Hyun Kim, Eun Joo Kang, Tae-Yong Kim, Yeon Hee Park, Ji-Youn Han, Il-Hwan Kim, Sang-We Kim, Dae Ho Lee, Jae Lyun Lee, Jae Cheol Lee, Chang-Min Choi, Changhoon Yoo, Shinkyo Yoon, Jae Ho Jeong, Seyoung Seo, Sun Young Kim, Jin-Hee Ahn, Sook Ryun Park
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 5209.
https://doi.org/10.1158/1538-7445.AM2022-5209
Published: 15 June 2022
View articletitled, Abstract 5209: Hyperprogression in various solid cancers treated with immune checkpoint inhibitors in the real world
Journal Articles

Abstract CT559: Capmatinib plus osimertinib vs platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIB/IIIC or IV EGFR-mutant, T790M-negative NSCLC harboring MET amplification

Yi-Long Wu, Ji-Youn Han, Terufumi Kato, Fabrice Barlesi, Edward B. Garon, Federico Cappuzzo, Yuji Shibata, Nathalie Smith, Sadhvi Khanna, Riccardo Belli, Alejandro Yovine, Daniel Tan
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT559.
https://doi.org/10.1158/1538-7445.AM2022-CT559
Published: 15 June 2022
View articletitled, Abstract CT559: Capmatinib plus osimertinib vs platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIB/IIIC or IV EGFR-mutant, T790M-negative NSCLC harboring MET amplification
Journal Articles

Abstract 5539: Nivolumab after cyclophosphamide and doxorubicin induction therapy in previously treated advanced non-squamousl non-small cell lung cancer with PD-L1<10%

Beung-Chul Ahn, Hyae Young Kim, Geon Kook Lee, Sang-Jin Lee, Ji-Eun Hwang, Kyoungsuk Kwon, Youngjoo Lee, Ji-Youn Han
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 5539.
https://doi.org/10.1158/1538-7445.AM2022-5539
Published: 15 June 2022
View articletitled, Abstract 5539: Nivolumab after cyclophosphamide and doxorubicin induction therapy in previously treated advanced non-squamousl non-small cell lung cancer with PD-L1&lt;10%
Journal Articles

Abstract CT127: Tumor response and MET-detection methods exploratory biomarker analysis of Part B of the Ph 1b TATTON study

Ryan Hartmaier, Ji-Youn Han, Byoung Chul Cho, Aleksandra Markovets, Nisha Kurian, Mireille Cantarini, Pasi A. Janne
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT127.
https://doi.org/10.1158/1538-7445.AM2021-CT127
Published: 01 July 2021
View articletitled, Abstract CT127: Tumor response and MET-detection methods exploratory biomarker analysis of Part B of the Ph 1b TATTON study
Journal Articles

Abstract CT024: Acquired resistance in patients with EGFRm NSCLC following treatment with osimertinib plus savolitinib in the Ph1b TATTON study Parts B and D

Aleksandra Markovets, Ji-Youn Han, Byoung Chul Cho, Mireille Cantarini, Pasi A. Janne, Ryan Hartmaier
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT024.
https://doi.org/10.1158/1538-7445.AM2021-CT024
Published: 01 July 2021
View articletitled, Abstract CT024: Acquired resistance in patients with EGFRm NSCLC following treatment with osimertinib plus savolitinib in the Ph1b TATTON study Parts B and D
Journal Articles

Abstract CT082: Capmatinib in METex14-mutated (mut) advanced non-small cell lung cancer (NSCLC): Results from the phase II GEOMETRY mono-1 study, including efficacy in patients (pts) with brain metastases (BM)

Edward B. Garon, Rebecca S. Heist, Takashi Seto, Ji-Youn Han, Noemi Reguart, Harry J. Groen, Daniel SW Tan, Toyoaki Hida, Maja J. de Jonge, Sergey V. Orlov, Egbert F. Smit, Pierre-Jean Souquet, Johan Vansteenkiste, Sylvie Le Mouhaer, Anna Robeva, Maeve Waldron-Lynch, Monica Giovannini, Juergen Wolf
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT082.
https://doi.org/10.1158/1538-7445.AM2020-CT082
Published: 15 August 2020
View articletitled, Abstract CT082: Capmatinib in METex14-mutated (mut) advanced non-small cell lung cancer (NSCLC): Results from the phase II GEOMETRY mono-1 study, including efficacy in patients (pts) with brain metastases (BM)
Journal Articles

Abstract CT303: The effect of savolitinib plus osimertinib on ctDNA clearance in patients with EGFR mutation positive (EGFRm) MET-amplified NSCLC in the TATTON study

Ryan Hartmaier, Ji-Youn Han, Myung-Ju Ahn, Byoung Chul Cho, Mireille Cantarini, Paul Frewer, Melanie M. Frigault, Geoffrey Oxnard
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT303.
https://doi.org/10.1158/1538-7445.AM2020-CT303
Published: 15 August 2020
View articletitled, Abstract CT303: The effect of savolitinib plus osimertinib on ctDNA clearance in patients with EGFR mutation positive (EGFRm) MET-amplified NSCLC in the TATTON study
Journal Articles

Abstract CT032: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior first/second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)

Helena Yu, Myung-Ju Ahn, Sang-We Kim, Byoung Chul Cho, Lecia Sequist, Sergey Orlov, Lone H. Ottesen, Remy B. Verheijen, Anders Mellemgaard, Jonathan Wessen, Ji-Youn Han
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT032.
https://doi.org/10.1158/1538-7445.AM2019-CT032
Published: 01 July 2019
View articletitled, Abstract CT032: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior first/second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
Journal Articles

Abstract 4897: Detection of MET-mediated EGFR tyrosine kinase inhibitor (TKI) resistance in advanced non-small cell lung cancer (NSCLC): biomarker analysis of the TATTON study

Ryan J. Hartmaier, Ji-Youn Han, Byoung Chul Cho, Melanie M. Frigault, Aleksandra Markovets, Anne L’Hernault, David Duncan, Pierre Lao-Sirieix, J. Carl Barrett, Remy B. Verheijen, Dana Ghiorghiu, Jonathan Wessen, Geoffrey R. Oxnard
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 4897.
https://doi.org/10.1158/1538-7445.AM2019-4897
Published: 01 July 2019
View articletitled, Abstract 4897: Detection of MET-mediated EGFR tyrosine kinase inhibitor (TKI) resistance in advanced non-small cell lung cancer (NSCLC): biomarker analysis of the TATTON study
Journal Articles

Abstract CT033: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)

Lecia V. Sequist, Jong Seok Lee, Ji-Youn Han, Wu-Chou Su, James Chih-Hsin Yang, Helena Yu, Lone H. Ottesen, Remy B. Verheijen, Anders Mellemgaard, Jonathan Wessen, Geoffrey Oxnard, Byoung Chul Cho
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT033.
https://doi.org/10.1158/1538-7445.AM2019-CT033
Published: 01 July 2019
View articletitled, Abstract CT033: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
Journal Articles

Abstract 3989: Dual targeting of ErbB2/ErbB3 for treatment of SCL3A2-NRG1-mediated lung cancer

Jeong Yeon Jo, Dong Hoon Shin, Ji-Youn Han
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 3989.
https://doi.org/10.1158/1538-7445.AM2018-3989
Published: 01 July 2018
View articletitled, Abstract 3989: Dual targeting of ErbB2/ErbB3 for treatment of SCL3A2-NRG1-mediated lung cancer
Journal Articles

Abstract CT079: ELUXA 1: Ph II study of BI1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)

Sai-Hong Ou, Keunchil Park, Ji-Youn Han, Dong-Wan Kim, Lyudmila Bazhenova, Yong-Kek Pang, How Soon Hin, Oscar Juan, Jeewoong Son, Isabelle Voccia, Daniel Massey, Miyoung Kim, Pasi A. Jänne
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT079.
https://doi.org/10.1158/1538-7445.AM2016-CT079
Published: 15 July 2016
View articletitled, Abstract CT079: ELUXA 1: Ph II study of BI1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)
Journal Articles

Abstract 97: A novel PTPRK-FILIP1 fusion gene in invasive mucinous adenocarcinoma of lung without known driver mutations

Sung-Hye Hong, Geon Kook Lee, Sang Hoon Song, Seung Youn Lee, Jin Young Kim, Ji-Youn Han
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 97.
https://doi.org/10.1158/1538-7445.AM2016-97
Published: 15 July 2016
View articletitled, Abstract 97: A novel PTPRK-FILIP1 fusion gene in invasive mucinous adenocarcinoma of lung without known driver mutations